KRBPQ (Kiromic BioPharma) Research & Development: $6.85 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kiromic BioPharma Research & Development?

Kiromic BioPharma KRBPQ Research & Development is $6.85 Mil as of Dec. 2024.

Research & Development is the aggregate amount of research and development expenses during the year. Kiromic BioPharma's Research & Development for the three months ended in Dec. 2024 was $-4.53 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $6.85 Mil.

Kiromic BioPharma  (OTCPK:KRBPQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kiromic BioPharma Research & Development Related Terms

Kiromic BioPharma Research & Development Historical Data

* Premium members only.

The historical data trend for Kiromic BioPharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiromic BioPharma Research & Development Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 5.05 11.37 13.92 6.95 6.85

Kiromic BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 3.02 4.14 4.23 -4.53

Kiromic BioPharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $6.85 Mil mean?
Kiromic BioPharma (KRBPQ) has a Research & Development of $6.85 Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on Kiromic BioPharma and its competitors.
Is Kiromic BioPharma's Research & Development too high?
Kiromic BioPharma's current Research & Development is $6.85 Mil.
How does Kiromic BioPharma's Research & Development compare to VRTX and REGN?
Kiromic BioPharma's Research & Development of $6.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kiromic BioPharma and its competitors. Kiromic BioPharma's current Research & Development is $6.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiromic BioPharma stock overvalued right now?
Kiromic BioPharma (KRBPQ) has a current Research & Development of $6.85 Mil. The current Research & Development is $6.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kiromic BioPharma (KRBPQ), the current Research & Development is $6.85 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiromic BioPharma Business Description

Address 7707 Fannin Street, Suite 200, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.